Tuesday 14 May 2013

International Symposium on “Rotavirus Vaccines For India- the Evidence and the Promise” Begins

 
A two day International Symposium on “Rotavirus Vaccines For India- The Evidence And The Promise” began here in New Delhi today with the inaugural remark by Dr. K. VijayRaghavan, Secretary Department of Bio-Technology (DBT) that this social innovation partnership showcases how our science and biomedical system is maturing. We have added to our know-how and capacity in ways that will pay dividends for the development of future solutions. 

Dr. Vijayraghwan highlighted the the long and unique road of this vaccine development project - an innovative international model of collaboration across agencies, sectors, continents, and cultures. He said Rotavirus is the most severe and lethal cause of childhood diarrhoea and kills around 100,000 Indian children each year and to combat it Indian and international researchers and the public and private sectors joined together to combat a terrible killersaid for this Indian and international researchers and the public and private sectors have joined together to develop this rotavirus vaccine was developed from an Indian strain by an Indian company, and tested by Indian investigators in an effort led by the Indian government. 

He said our job has been to do the research and development of the innovative solutions and we have had help from global scientists and friends—and the result is a world-class vaccine for India’s children and for r the first time, we have taken a vaccine from the earliest discovery through every stage of development. Also, this this entire research effort has met strict international standards ethics and quality. And from here, the health ministry will take this forward and make the decision about licensure and introduction. He specially thanked Dr. M.K.Bhan, Former Secretary DBT for having a tireless stint in fostering the social innovation partnership and ensuring the highest standards for the vaccine. 

This International Symposium is a joint venture of Department of Biotechnology, M/o Science & Technology Department of Health Research/Indian Council for Medical Research and Indian Academy of Paediatrics and likely to discuss following issues: ROTAVAC – a new rotavirus vaccine; Rotavirus Disease in India; Licensed Rotavirus Vaccines ; Global experience of rotavirus vaccines and Recommendations for Future Efforts . 

No comments:

Extension of Emergency Credit Line Guarantee Scheme through ECLGS 2.0 for the 26 sectors identified by the Kamath Committee and the healthcare sector

Extension of the duration of Emergency Credit Line Guarantee Scheme (ECLGS) 1.0 The Government has extended Emergency Credit Line Guarantee ...